Achieve Life Sciences Inc. Common Shares (ACHV)

About ACHV

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD an…

Sector

Health Care

Industry

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Employees

28

Website

achievelifesciences.com/

Fundamentals

1-day range

$7.95$8.22

Market cap

$648.81M

P/E (trailing)

—

P/E (forward)

-12.73

EPS (trailing)

$-1.11

Dividend yield

—

Beta

2.38

Avg. volume

1.81M

Dividend pay date

July 31, 2020

Forecasts

12 analyst ratings

Achieve Life Sciences Inc. Common Shares Competitors

Chosen by industry and closest market cap.

• ACHV

  Achieve Life Sciences Inc. Common Shares

  $8.09

  ▼ 1.16%
  Market cap $648.81MP/E —
  $2.62$8.61
• TKNO

  Alpha Teknova Inc. Common Stock

  $7.13

  ▼ 2.46%
  Market cap $284.15MP/E —
  $1.91$7.84
• IMDX

  Insight Molecular Diagnostics Inc. Common Stock

  $4.16

  ▼ 3.03%
  Market cap $162.42MP/E —
  $2.33$8.51
• CDIO

  Cardio Diagnostics Holdings Inc. Common stock

  $1.84

  ▼ 1.60%
  Market cap $4.85MP/E —
  $0.97$7.91
• BMRA

  Biomerica Inc. Common Stock

  $2.14

  ▲ 1.67%
  Market cap $4.73MP/E —
  $1.45$3.31
• VRAX

  Virax Biolabs Group Limited Ordinary Shares

  $2.82

  ▼ 4.08%
  Market cap $2.34MP/E —
  $2.5$21.75
• NTLA

  Intellia Therapeutics Inc. Common Stock

  $12.87

  ▼ 1.83%
  Market cap $1.50BP/E —
  $7.95$28.25

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Achieve Life Sciences Enters ATM Sale Agreement With Jefferies For Up To $150M In Common Stock
  benzinga · 8/14/2026
• Achieve Life Sciences Enters ATM Sale Agreement With Jefferies For Up To $150M In Common Stock
  Benzinga · 8/14/2026
• This Vail Resorts Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
  Benzinga · 8/13/2026
• Morgan Stanley Initiates Coverage On Achieve Life Sciences with Overweight Rating, Announces Price Target of $13
  Benzinga · 8/13/2026
• Achieve Life Sciences Q2 EPS $(0.80) Misses $(0.16) Estimate
  Benzinga · 8/11/2026

• Reid Alexander Waldman · July 27, 2026 · Grant

  16.7K
• Reid Alexander Waldman · July 27, 2026 · Grant

  25.0K
• Martin Christopher Nathan · July 27, 2026 · Grant

  16.7K
• Martin Christopher Nathan · July 27, 2026 · Grant

  25.0K
• Sellig Thomas · July 27, 2026 · Grant

  16.7K
• Sellig Thomas · July 27, 2026 · Grant

  25.0K
• Phelan Nancy R. · July 27, 2026 · Grant

  16.7K
• Phelan Nancy R. · July 27, 2026 · Grant

  25.0K
• Royston Aaron · July 27, 2026 · Grant

  16.7K
• Royston Aaron · July 27, 2026 · Grant

  25.0K
• Richard Alistair Stewart · July 27, 2026 · Grant

  16.7K
• Richard Alistair Stewart · July 27, 2026 · Grant

  25.0K
• Jeffrey S. Farrow · July 27, 2026 · Grant

  16.7K
• Jeffrey S. Farrow · July 27, 2026 · Grant

  25.0K
• Reid Alexander Waldman · May 29, 2026 · Grant

  47.3K

Institutional Ownership

March 31, 2026

Total shares held

21.81M

Total value held

$64.31M

Institutional holders

79